Trial Profile

A Phase I Trial of Ulixertinib (BVD-523) in Combination With Palbociclib in Patients With Advanced Solid Tumors With Expansion Cohort in Previously Treated Metastatic Pancreatic Cancer and Metastatic RAS-mutant and NF1-mutant (no Concurrent BRAFV600 Mutations) Melanoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Palbociclib (Primary) ; Ulixertinib (Primary)
Indications Cholangiocarcinoma; Gastrointestinal stromal tumours; Malignant melanoma; Pancreatic cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use

02 Aug 2024 Planned End Date changed from 24 Apr 2026 to 24 Nov 2026.
02 Aug 2024 Planned primary completion date changed from 15 Jul 2024 to 1 Aug 2025.
18 Nov 2022 Status changed from active, no longer recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com